A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
BRUNELLO
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema
1 other identifier
interventional
984
19 countries
178
Brief Summary
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Aug 2024
Typical duration for phase_2
178 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 7, 2024
CompletedFirst Submitted
Initial submission to the registry
August 20, 2024
CompletedFirst Posted
Study publicly available on registry
August 26, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
August 12, 2025
October 1, 2024
2.1 years
August 20, 2024
August 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline Best-Corrected Visual Acuity measured using the standardized ETDRS chart
Change from baseline Best-Corrected Visual Acuity measured using the standardized ETDRS chart
52 Weeks
Secondary Outcomes (1)
Changes in structural and visual outcomes
Duration of the study, through Week 104
Study Arms (3)
EYE103 Low Dose Treatment Arm
EXPERIMENTALEYE103 Low Dose Treatment Arm
EYE103 High Dose Treatment Arm
EXPERIMENTALEYE103 High Dose Treatment Arm
Ranibizumab Treatment Arm
ACTIVE COMPARATORRanibizumab Treatment Arm
Interventions
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
EYE103 is a humanized antibody formulated for intravitreal administration
Eligibility Criteria
You may qualify if:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a HbA1c of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of DME.
You may not qualify if:
- Be pregnant or breastfeeding
- History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
- Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
- Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
- If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept \[2 mg\], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- EyeBiotech Ltd.lead
Study Sites (183)
Scottsdale
Scottsdale, Arizona, 85255, United States
Fayetteville, Arkansas
Fayetteville, Arkansas, 72703, United States
Springdale, Arkansas
Springdale, Arkansas, 72764, United States
Bakersfield, CA
Bakersfield, California, 93309, United States
Glendale, CA
Glendale, California, 91204, United States
Modesto, CA
Modesto, California, 95356, United States
Mountain View, CA
Mountain View, California, 94040, United States
Redlands, CA
Redlands, California, 92374, United States
Sacramento, CA
Sacramento, California, 95825, United States
Sacramento, CA
Sacramento, California, 95841, United States
Santa Ana
Santa Ana, California, 92705, United States
Colorado Springs, CO
Colorado Springs, Colorado, 80909, United States
Denver, Colorado
Denver, Colorado, 80210, United States
Danbury, CT
Danbury, Connecticut, 06810, United States
Manchester, CT
Manchester, Connecticut, 06042, United States
Waterford,CT
Waterford, Connecticut, 06385, United States
Deerfield Beach, FL
Deerfield Beach, Florida, 33064, United States
Fort Lauderdale, FL
Fort Lauderdale, Florida, 33308, United States
Fort Myers,FL
Fort Myers, Florida, 33912, United States
Gainesville, FL
Gainesville, Florida, 32607, United States
Orlando, Florida
Orlando, Florida, 32806, United States
Plantation, FL
Plantation, Florida, 33324, United States
Sarasota, FL
Sarasota, Florida, 34232, United States
Saint Petersburg, FL
St. Petersburg, Florida, 33711, United States
Tallahassee, FL
Tallahassee, Florida, 32308, United States
Tampa, FL
Tampa, Florida, 33609-4614, United States
Tampa, FL
Tampa, Florida, 33617, United States
Winter Haven, FL
Winter Haven, Florida, 33880, United States
Lemont, IL
Lemont, Illinois, 60439, United States
Springfield, Illinois
Springfield, Illinois, 62702, United States
West Des Moines, IA
West Des Moines, Iowa, 50266, United States
Lenexa, Kansas
Lenexa, Kansas, 66215, United States
Wichita, Kansas
Wichita, Kansas, 67214, United States
Portland, Maine
Portland, Maine, 04101, United States
Hagerstown, MD
Hagerstown, Maryland, 21740, United States
Springfield,MA
Springfield, Massachusetts, 01107, United States
Grand Rapids, Michigan
Grand Rapids, Michigan, 49546, United States
Minneapolis, MN
Minneapolis, Minnesota, 55435, United States
Madison, MS
Madison, Mississippi, 39110, United States
Bloomfield, NJ
Bloomfield, New Jersey, 07003, United States
Cherry Hill, NJ
Cherry Hill, New Jersey, 08034, United States
Liverpool, NY
Liverpool, New York, 13088, United States
Oceanside, NY
Oceanside, New York, 11572, United States
Rochester, NY
Rochester, New York, 14620, United States
Asheville, NC
Asheville, North Carolina, 28803, United States
Hickory, NC
Hickory, North Carolina, 28602, United States
Wake Forest, MC
Wake Forest, North Carolina, 27587, United States
Winston Salem, NC
Winston-Salem, North Carolina, 27103, United States
Cleveland, Ohio
Cleveland, Ohio, 44122, United States
Cleveland, OH
Cleveland, Ohio, 44130, United States
Youngstown, Ohio
Youngstown, Ohio, 44505, United States
Edmond, OK
Edmond, Oklahoma, 73013, United States
Portland, OR
Portland, Oregon, 97221, United States
Springfield, Oregon
Springfield, Oregon, 97477, United States
Bethlehem, PA
Bethlehem, Pennsylvania, 18017, United States
Erie, PA
Erie, Pennsylvania, 16507, United States
Beaufort, SC
Beaufort, South Carolina, 29902, United States
Florence, SC
Florence, South Carolina, 29501, United States
Ladson, SC
Ladson, South Carolina, 29456, United States
West Columbia, SC
West Columbia, South Carolina, 29169, United States
Germantown, TN
Germantown, Tennessee, 38138, United States
Hixson, Tennessee
Hixson, Tennessee, 37343, United States
Johnson City, Tennessee
Johnson City, Tennessee, 37604, United States
Knoxville, TN
Knoxville, Tennessee, 37922, United States
Nashville, TN
Nashville, Tennessee, 37203, United States
Abilene, TX
Abilene, Texas, 79606, United States
Amarillo, TX
Amarillo, Texas, 79106, United States
Amarillo, TX
Amarillo, Texas, 79109, United States
Arlington, TX
Arlington, Texas, 76012, United States
Austin, TX
Austin, Texas, 78705, United States
Beaumont, TX
Beaumont, Texas, 77707, United States
Bellaire, TX
Bellaire, Texas, 77401, United States
Dallas, TX
Dallas, Texas, 75231, United States
Fort Worth, TX
Fort Worth, Texas, 76104, United States
Katy, TX
Katy, Texas, 77494, United States
Plano, TX
Plano, Texas, 75075, United States
Round Rock, TX
Round Rock, Texas, 78681, United States
San Antonio, TX
San Antonio, Texas, 78240, United States
Schertz, Texas
Schertz, Texas, 78154, United States
The Woodlands, TX
The Woodlands, Texas, 77384, United States
Willow Park, TX
Willow Park, Texas, 76087, United States
Salt Lake City, Utah
Salt Lake City, Utah, 84107, United States
Lynchburg, VA
Lynchburg, Virginia, 24502, United States
Richmond, Virginia
Richmond, Virginia, 23235, United States
Spokane, WA
Spokane, Washington, 99204, United States
Ciudad de Cordoba, Argentina
Córdoba, Argentina, X5000AAJ, Argentina
Buenos Aires, Argentina
CABA, Buenos Aires, 1015, Argentina
Buenos Aires, Argentina
CABA, Buenos Aires, 1120, Argentina
Buenos Aires, Argentina
CABA, Buenos Aires, C1033AAW, Argentina
Caba, Buenos Aires, Argentina
Caba, Buenos Aires, C1116ABA, Argentina
Cordoba, Argentina
Córdoba, Córdoba Province, 5000, Argentina
Santa Fe, Argentina
Rosario, Santa Fe Province, S2000DSK, Argentina
Santa Fe, Argentina
Rosario, Sante Fe, 2000, Argentina
Buenos Aires, Argentina
CABA, 1023, Argentina
Albury, Australia
Albury, Australia, 2640, Australia
Parramatta, Australia
Parramatta, Australia, 2150, Australia
Sydney, Australia
Sydney, Australia, 2000, Australia
Sydney Retina Clinic
Sydney, New South Wales, 2000, Australia
Sydney, Australia
Sydney, New South Wales, 2135, Australia
Innsbruck, Austria
Innsbruck, Austria, 6020, Austria
Vienna, Austria
Vienna, Vienna, 1090, Austria
Graz, Austria
Graz, 8036, Austria
Vienna, Austria
Vienna, 1140, Austria
Medellin, Colombia
Medellín, Antioquia, 50021, Colombia
Barranquilla, Colombia
Barranquilla, Atlántico, 80002, Colombia
Medellin, Colombia
Medellín, Colombia, 50016, Colombia
Bogota, Columbia
Bogotá, Columbia, 110231, Colombia
Cali, Colombia
Cali, Valle del Cauca Department, 760042, Colombia
Osijek, Croatia
Osijek, 31000, Croatia
Prague, Czechia
Prague, Prague, 1150/50, Czechia
Mlada Boleslav, Czechia
Mladá Boleslav, 293 01, Czechia
Nachod, Czechia
Náchod, 547 01, Czechia
Prague, Czechia
Prague, Czechia
Cedex, France
Dijon, Cedex, 21079, France
Lyon, France
Lyon, France, 69004, France
Paris, France
Paris, Paris, 75019, France
Creteil, France
Créteil, 94010, France
Marseille, France
Marseille, 13008, France
Paris, France
Paris, 75006, France
Paris, France
Paris, 75015, France
Saint Cyr sur Loire, France
Saint-Cyr-sur-Loire, 37540, France
Frankfurt, Germany
Frankfurt, Germany, 60590, Germany
Hanover, Germany
Hanover, Germany, 30625, Germany
Munchen, Germany
München, Germany, 80336, Germany
Munster, Germany
Münster, Germany, 48145, Germany
Budapest, Hungary
Budapest, Budapest, H-1085, Hungary
Budapest, Hungary
Budapest, Hungary, H-1062, Hungary
Budapest, Hungary
Budapest, Hungary, H-1106, Hungary
Debrecen, Hungary
Debrecen, Hungary, H-4032, Hungary
Zalaegerszeg, Hungary
Zalaegerszeg, Hungary, 8900, Hungary
Budapest, Hungry
Budapest, H-1133, Hungary
Pecs, Hungary
Pécs, H-7621, Hungary
Szeged, Hungary
Szeged, H-6720, Hungary
Rehovot, Israel
Rehovot, Israel, 76100, Israel
Beer Yakov, Israel
Be’er Ya‘aqov, 70300, Israel
Haifa, Israel
Haifa, 3436212, Israel
Jerusalem, Israel
Jerusalem, 9112001, Israel
Petah Tikva, Israel
Petah Tikva, 49100, Israel
Tel Aviv, Israel
Tel Aviv, 6423906, Israel
Bologna, Italy
Bologna, Italy, 40138, Italy
Milano, Italy
Milan, Italy, 20157, Italy
Roma, Italy
Roma, Italy, 00168, Italy
Udine, Italy
Udine, Italy, 33100, Italy
Milano, Italy
Milan, Milano, 20132, Italy
Rome, Italy
Rome, Rome, 81.00133, Italy
Firenze, Italy
Florence, 50139, Italy
Milano, Italy
Milan, 20122, Italy
Riga, Latvia
Riga, Rīga, LV1002, Latvia
Riga, Latvia
Riga, Rīga, LV1006, Latvia
Gdansk, Poland
Gdansk, Gdansk, 80-809, Poland
Bialystok, Poland
Bialystok, Poland, 15-866, Poland
Bydgoszcz, Poland
Bydgoszcz, Poland, 85-309, Poland
Katowice, Poland
Katowice, Poland, 40-594, Poland
Krakow, Poland
Krakow, Poland, 31-501, Poland
Tarnowskie Gory, Poland
Tarnowskie Góry, Poland, 42-600, Poland
Bydgoszcz, Poland
Bydgoszcz, 85-631, Poland
Gdansk, Poland
Gdansk, 80-809, Poland
Olsztyn, Poland
Olsztyn, 10-424, Poland
Porto, Portugal
Porto, Porto District, 4200-319, Portugal
Coimbra, Portugal
Coimbra, 3000-548, Portugal
Coimbra, Portugal
Coimbra, 3030-163, Portugal
Arecibo, PR
Arecibo, PR, 00612, Puerto Rico
Trebisov, Slovakia
Trebišov, Slovakia, 075 01, Slovakia
Trencin, Slovakia
Trenčín, Slovakia, 911 01, Slovakia
Zilina, Slovakia
Žilina, Slovakia, 012 07, Slovakia
Barcelona, Spain
Barcelona, Barcelona, 08195, Spain
Sevilla, Spain
Seville, Sevilla, 41009, Spain
Barcelona, Spain
Barcelona, Spain, 08021, Spain
Barcelona, Spain
Barcelona, Spain, 08035, Spain
Santiago de Compostela, Spain
Santiago de Compostela, Spain, 15706, Spain
Zaragoza, Spain
Zaragoza, Spain, 50009, Spain
Valencia, Spain
Burjassot, Valencia, 46100, Spain
Barcelona, Spain
Barcelona, 08022, Spain
Ankara, Turkey
Ankara, Turkey, 06230, Turkey (Türkiye)
Ankara, Turkey
Ankara, Turkey, 06490, Turkey (Türkiye)
Balcova, Turkey
Balçova, Turkey, 35330, Turkey (Türkiye)
London, UK
London, Middlesex, NW10 7NS, United Kingdom
Bradford, United Kingdom
Bradford, United Kingdom, BD9 6RJ, United Kingdom
Liverpool, United Kingdom
Liverpool, United Kingdom, L7 8YA, United Kingdom
Sunderland, United Kingdom
Sunderland, United Kingdom, SR2 9HP, United Kingdom
Wolverhamptom, United Kingdom
Wolverhampton, United Kingdom, WV10 0QP, United Kingdom
York, United Kingdom
York, UnitedKingdom, YO10 4DZ, United Kingdom
Bristol, UK
Bristol, BS1 2LX, United Kingdom
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Charles Miller, MD PhD
EyeBiotech Ltd.
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 20, 2024
First Posted
August 26, 2024
Study Start
August 7, 2024
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
December 31, 2027
Last Updated
August 12, 2025
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share